BeiGene Announces Inclusion in FTSE Russell Indices
September 20 2021 - 7:00AM
Business Wire
BeiGene added to FTSE Global Equity Index Large
Cap, All-World (LM), All-Cap (LMS), Total-Cap (LMSµ); as well as
the Developed ESG Low Carbon Select Index and Asia ex Japan ESG Low
Carbon Select Index
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global
biotechnology company focused on developing and commercializing
innovative medicines worldwide, has announced its inclusion in
several FTSE Russell indices, including: the FTSE Global Equity
Index Large Cap; the FTSE All-World (LM); the FTSE All-Cap (LMS);
and the FTSE Total-Cap (LMSµ). In addition, BeiGene has also been
included in the FTSE Developed ESG Low Carbon Select Index, and the
FTSE Asia ex Japan ESG Low Carbon Select Index, reflecting the
company’s commitment to sustainability. The company’s inclusion on
the FTSE indices became effective on Friday, September 17, 2021,
after U.S. market close.
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics, and data solutions for investors
worldwide. FTSE Russell calculates thousands of indexes that
measure and benchmark markets and asset classes in more than 70
countries, covering 98 percent of the investable market globally.
According to FTSE Russell, a core set of universal principles
guides FTSE Russell index design and management: a transparent
rules-based methodology is informed by independent committees of
leading market participants.
“BeiGene’s inclusion on these indices has the potential to
elevate our visibility among the global investment community and
diversify our overall investor base,” said John V. Oyler,
Co-Founder, Chairman and CEO of BeiGene. “Our more than 7,000
colleagues on five continents share a commitment to operating with
urgency to change how cancer is treated globally, while operating
with the highest integrity.”
BeiGene’s environmental, social and governance (ESG) approach
centers on its ambition to expand affordable access to treatments
for more patients around the world; to provide meaningful growth
and development opportunities for its employees; and to operate its
business responsibly and sustainably.
Added Christine Riley Miller, Reputation & ESG Lead at
BeiGene, “We are determined to not only create world-class
therapies for all, but also to do our part in creating a more
inclusive, equitable, and sustained world. Our ESG framework
reflects our aspiration to increase access and affordability of
cancer treatments for all who need them.”
More information about BeiGene’s ESG efforts can be found in the
company’s inaugural global ESG report.
For more information, please refer to the Index page on FTSE’s
website at https://www.ftserussell.com/products/indices/esg.
About BeiGene
BeiGene is a global, science-driven biotechnology company
focused on developing innovative and affordable medicines to
improve treatment outcomes and access for patients worldwide. With
a broad portfolio of more than 40 clinical candidates, we are
expediting development of our diverse pipeline of novel
therapeutics through our own capabilities and collaborations. We
are committed to radically improving access to medicines for two
billion more people by 2030. BeiGene has a growing global team of
over 7,000 colleagues across five continents. To learn more about
BeiGene, please visit www.beigene.com and follow us on Twitter at
@BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene’s plans, commitments, aspirations, and goals, such as the
aspiration to increase access and affordability of cancer treatment
for patients worldwide. Actual results may differ materially from
those indicated in the forward-looking statements as a result of
various important factors, including BeiGene's ability to
demonstrate the efficacy and safety of its drug candidates; the
clinical results for its drug candidates, which may not support
further development or marketing approval; actions of regulatory
agencies, which may affect the initiation, timing and progress of
clinical trials and marketing approval; BeiGene's ability to
achieve commercial success for its marketed medicines and drug
candidates, if approved; BeiGene's ability to obtain and maintain
protection of intellectual property for its medicines and
technology; BeiGene's reliance on third parties to conduct drug
development, manufacturing and other services; BeiGene’s limited
experience in obtaining regulatory approvals and commercializing
pharmaceutical products and its ability to obtain additional
funding for operations and to complete the development and
commercialization of its drug candidates and achieve and maintain
profitability; the impact of the COVID-19 pandemic on the BeiGene’s
clinical development, regulatory, commercial, and other operations,
as well as those risks more fully discussed in the section entitled
“Risk Factors” in BeiGene’s most recent quarterly report on Form
10-Q as well as discussions of potential risks, uncertainties, and
other important factors in BeiGene's subsequent filings with the
U.S. Securities and Exchange Commission. All information in this
press release is as of the date of this press release, and BeiGene
undertakes no duty to update such information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210920005241/en/
Investor Contact Gabrielle Zhou +86 10-5895-8058 or +1
857-302-5189 ir@beigene.com
Media Contact Emily Collins +1 201-201-4570
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2024 to May 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From May 2023 to May 2024